2009 – A Big Year for the BTK

Inside BIO Industry Analysis

The Amex Biotech Index, the BTK, outpaced its peer, the Nasdaq Biotech Index, by 29% and was 22% above the SP500.   Most of this can be attributed to 3rd quarter performance when Human Genome Sciences (HGSI) released P3 data for their antibody drug for Lupus. HGSI gained 555% in 3Q09, and the impact on the 20 company BTK can be seen in the lower bar chart. *

*It should be noted that both major biotech indices hold HGSI, but BTK, due to its equal weighting of only 20 companies (each rebalanced to 5% quarterly), can see more impact from a single company. HGSI in the Nasdaq Biotech Index (NBI) was less than 1% of the NBI prior to the July press release. The NBI is currently comprised of 125 companies, and is market cap weighted, dwarfing the impact of single small company news.

Inside BIO Industry Analysis  |  Email This Post  |  Printer Friendly
Tags: , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>